The Continuous Glucose Monitoring market has grown rapidly over the last decade, expanding from $2.8 billion in 2015 to $5.2 billion in 2020, representing a CAGR of 12.0%. Increasing diabetes prevalence, technological advancements in minimally invasive sensors, and rising patient awareness are key drivers. The market is projected to reach $7.8 billion in 2025 and exceed $14.2 billion by 2030, at a forecast CAGR of 12.4% from 2025–2030.

Historical Market Trends

Between 2015 and 2020, continuous glucose monitoring (CGM) devices recorded consistent growth: $2.8 billion in 2015, $3.2 billion in 2016, $3.6 billion in 2017, $4.2 billion in 2018, and $5.2 billion in 2020. Year-over-year growth averaged 11–13%, with a temporary slowdown in 2017 due to supply chain constraints. By 2021, the market reached $5.6 billion, a 7.7% YoY increase, followed by $6.2 billion in 2022 (10.7% growth) and $6.9 billion in 2023 (11.3% growth).

Regional Insights

North America remains the largest regional market, generating $2.8 billion in 2023, representing 40% of global revenue, up from $2.0 billion in 2019, growing at a 9.4% CAGR. Europe contributed $1.8 billion (26%), while Asia-Pacific grew fastest with a 15.2% CAGR, reaching $1.4 billion in 2023, up from $700 million in 2019. Latin America and MEA combined accounted for 8% of global revenue ($560 million), with a CAGR of 12.5%.

Device Type Segmentation

The CGM market is primarily segmented into:

• Real-Time CGM (rtCGM) – Dominates with 60% share ($4.2 billion in 2023), up from $2.7 billion in 2019, CAGR 13.0%.
• Intermittently Scanned CGM (isCGM) – Growing at 11.8% CAGR, revenue increased from $900 million in 2019 to $1.6 billion in 2023.
• Professional CGM Devices – Accounted for $450 million in 2023, up from $300 million in 2019, CAGR 10.1%.

End-Use Applications

Diabetes management remains the largest application, contributing 78% of global revenue ($5.4 billion) in 2023. Hospital and clinical monitoring applications generated $1.2 billion, while research and pharmaceutical applications contributed $250 million. Adoption in type 1 diabetes patients accounted for 42% of revenue, with type 2 patients comprising 36%, reflecting the growing use in insulin-treated populations.

Production Volumes and Investments

Global CGM production reached 18.6 million units in 2023, up from 12.4 million units in 2019, showing a 9.8% CAGR. Investments in sensor technology, wearable integration, and telemedicine solutions totaled $620 million in 2023, compared to $430 million in 2019. Leading companies, including Dexcom, Abbott, and Medtronic, invested between $80 million and $200 million in R&D and manufacturing upgrades from 2021–2023.

Market Drivers

1. Rising Diabetes Prevalence – Global diabetic population reached 537 million in 2023, up 4.8% from 2022, driving CGM adoption.
2. Technological Innovation – New non-invasive and implantable sensors increased patient adoption by 15% YoY in 2023.
3. Remote Patient Monitoring – Integration with mobile apps and cloud platforms grew 18% annually, enhancing continuous monitoring usage.

Market Restraints

• High Device Cost – CGM systems average $1,200–$2,500 per year, limiting adoption in low-income regions.
• Insurance Coverage Limitations – Only 65% of eligible patients in the US receive insurance reimbursement for CGM.
• Regulatory Delays – In emerging markets, regulatory approval can take 18–24 months, restricting timely market entry.

Future Projections

The CGM market is expected to reach $7.8 billion by 2025, with a 12.4% CAGR, and $14.2 billion by 2030. Asia-Pacific is projected to reach $3.2 billion by 2030, surpassing Europe as the second-largest regional market. Real-time CGM devices are forecasted to maintain 60–62% market share by 2030, while intermittently scanned CGM adoption will grow at 11.5% CAGR, driven by affordability and ease of use.

Industry Rankings

• Top 5 Players by Revenue in 2023:
  1. Dexcom – $2.1 billion
  2. Abbott Laboratories – $1.9 billion
  3. Medtronic – $1.2 billion
  4. Roche Diagnostics – $780 million
  5. Senseonics – $420 million

These companies collectively hold 78% of global market share, indicating a highly consolidated landscape with innovation-driven competition.

Government and Institutional Influence

Government and healthcare programs globally allocated $1.05 billion in 2023 to support CGM adoption, including subsidies, reimbursement initiatives, and patient awareness campaigns. The US, Germany, and Japan accounted for $620 million, promoting adoption in insulin-treated diabetic populations.

Conclusion

The Continuous Glucose Monitoring market demonstrates strong, data-backed growth, rising from $2.8 billion in 2015 to $6.9 billion in 2023, with projections reaching $7.8 billion in 2025 and $14.2 billion by 2030. Growth is driven by rising diabetes prevalence, technological advancements, and expanding remote monitoring applications. Real-time CGM dominates, while Asia-Pacific is the fastest-growing region. Continued R&D and adoption in type 2 diabetes populations will sustain a CAGR above 12%, positioning CGM as a critical component of diabetes management.

Read Full Research Study: Continuous Glucose Monitoring https://marketintelo.com/report/continuous-glucose-monitoring-market